Trends in Cancer
Science & SocietyMigrastatics: Redirecting R&D in Solid Cancer Towards Metastasis?
Section snippets
Acknowledgments
J.B. and D.R. are supported by Czech Science Foundation grant 18-15684J, the Ministry of Education, Youth, and Sports of the Czech Republic within the LQ1604 National Sustainability Program II (Project BIOCEV-FAR), and by project ‘Center for Tumor Ecology – Research of the Cancer Microenvironment Supporting Cancer Growth and Spread’ (CZ.02.1.01/0.0/0.0/16_019/0000785) supported by the Operational Programme Research, Development, and Education. V.S.M. was supported by Cancer Research UK (CRUK)
References (14)
- et al.
Cancer, checkpoint inhibitors, and confusion
Lancet Oncol.
(2017) Migrastatics – anti-metastatic and anti-invasion drugs: promises and challenges
Trends Cancer
(2017)- et al.
Limits to precision cancer medicine
N. Engl. J. Med.
(2016) Calling time on the immunotherapy gold rush
Lancet Oncol.
(2017)Solid cancer: the new tumour spread endpoint opens novel opportunities
Br. J. Cancer
(2019)Pragmatic medicine in solid cancer: a translational alternative to precision medicine
Onco. Targets Ther.
(2016)Apalutamide treatment and metastasis-free survival in prostate cancer
N. Engl. J. Med.
(2018)
Cited by (24)
Recently reported cell migration inhibitors: Opportunities and challenges for antimetastatic agents
2024, Drug Discovery TodayTherapeutic potential and limitations of curcumin as antimetastatic agent
2023, Biomedicine and PharmacotherapyEngine shutdown: migrastatic strategies and prevention of metastases
2023, Trends in CancerPAK-dependent regulation of actin dynamics in breast cancer cells
2022, International Journal of Biochemistry and Cell BiologyCitation Excerpt :Unfortunately, improvement in these survival rates does not equally reflect those with metastatic cancer. Until recently, a prerequisite for cancer treatment was tumour shrinkage, highlighting how the end point of therapeutic design is still focussed on the primary tumour (Rosel et al., 2019). We have reviewed how PAKs are implicated in BCa cell actin dynamics to modulate cytoskeletal extensions, cell adhesion, actomyosin contractility, and degradative invasion to overall promote BCa metastatic dissemination (Fig. 2).
MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours
2021, Cancer LettersCitation Excerpt :Alterations in the activity of proteins that regulate cytoskeleton organization can influence the adhesive and invasive properties of tumour cells, as well as their proliferation and survival [8]. As a result, considerable effort has been focussed on identifying cytoskeleton regulators that are co-opted, mutated or differentially expressed in tumours because of their potential as cancer therapeutic targets [9]. Extracellular signals initiate the recruitment of protein complexes that catalyze the polymerization of actin monomers into filaments at cell leading edges [10].
Say no to drugs: Bioactive macromolecular therapeutics without conventional drugs
2021, Journal of Controlled ReleaseCitation Excerpt :Inhibition of cancer cell extravasation and metastasis formation. Even though the mortality of patients with solid tumors is contributed to metastasis in 90% of the cases, there are not many examples of antimetastatic and antiinvasive drugs [60,61]. This clearly indicates a need to design molecularly targeted antimetastatic treatments [62].